📊 SONM Key Takeaways
Is DNA X, Inc. (SONM) a Good Investment?
DNA X faces imminent financial distress with negative stockholders equity (-$8M), critical liquidity crisis ($1.3M cash vs -$23.5M operating cash burn), and ongoing operational losses despite 14.5% revenue growth. The company will exhaust cash reserves within weeks at current burn rates and cannot service debt obligations.
Why Buy DNA X, Inc. Stock? SONM Key Strengths
- Revenue growth of 14.5% YoY demonstrates market demand
- Gross margin of 25% indicates product has some pricing power
- EPS improved 77.7% YoY (though remains deeply negative)
SONM Stock Risks: DNA X, Inc. Investment Risks
- Negative stockholders equity of -$8M (technical insolvency)
- Critical liquidity: $1.3M cash with -$23.5M operating cash burn (weeks of runway)
- Negative operating margins (-12.3%) with losses expanding despite revenue growth
- Current ratio 0.60x / Quick ratio 0.37x unable to cover near-term obligations
- Negative interest coverage (-5.7x) - cannot service $5.1M debt from operations
- Operating cash flow deterioration dominates revenue gains
Key Metrics to Watch
- Operating cash flow (currently -$23.5M)
- Cash burn rate and months of runway remaining
- Stockholders equity recovery timeline
- Debt refinancing capability and maturity schedule
DNA X, Inc. (SONM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
SONM Profit Margin, ROE & Profitability Analysis
SONM vs Telecom Sector: How DNA X, Inc. Compares
How DNA X, Inc. compares to Telecom sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is DNA X, Inc. Stock Overvalued? SONM Valuation Analysis 2026
Based on fundamental analysis, DNA X, Inc. has mixed fundamental signals relative to the Telecom sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
DNA X, Inc. Balance Sheet: SONM Debt, Cash & Liquidity
SONM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: DNA X, Inc.'s revenue has declined by 19% over the 5-year period, indicating business contraction. The most recent EPS of $-128.37 indicates the company is currently unprofitable.
SONM Revenue Growth, EPS Growth & YoY Performance
SONM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $15.0M | -$2.5M | $-4.83 |
| Q2 2025 | $11.2M | -$6.6M | $-0.79 |
| Q1 2025 | $9.1M | $458.0K | $0.08 |
| Q3 2024 | $9.1M | $527.0K | $0.12 |
| Q2 2024 | $11.5M | $509.0K | $0.11 |
| Q1 2024 | $16.8M | $227.0K | $0.01 |
| Q3 2023 | $20.5M | $527.0K | $0.01 |
| Q2 2023 | $12.0M | $509.0K | $0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
DNA X, Inc. Dividends, Buybacks & Capital Allocation
SONM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for DNA X, Inc. (CIK: 0001178697)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SONM
What is the AI rating for SONM?
DNA X, Inc. (SONM) has an AI rating of STRONG SELL with 98% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SONM's key strengths?
Claude: Revenue growth of 14.5% YoY demonstrates market demand. Gross margin of 25% indicates product has some pricing power.
What are the risks of investing in SONM?
Claude: Negative stockholders equity of -$8M (technical insolvency). Critical liquidity: $1.3M cash with -$23.5M operating cash burn (weeks of runway).
What is SONM's revenue and growth?
DNA X, Inc. reported revenue of $44.1M.
Does SONM pay dividends?
DNA X, Inc. does not currently pay dividends.
Where can I find SONM SEC filings?
Official SEC filings for DNA X, Inc. (CIK: 0001178697) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SONM's EPS?
DNA X, Inc. has a diluted EPS of $-28.58.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SONM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, DNA X, Inc. has a STRONG SELL rating with 98% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SONM stock overvalued or undervalued?
Valuation metrics for SONM: ROE of N/A (sector avg: 15%), net margin of -46.8% (sector avg: 14%). Compare these metrics with sector averages to assess valuation.
Should I buy SONM stock in 2026?
Our dual AI analysis gives DNA X, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SONM's free cash flow?
DNA X, Inc.'s operating cash flow is $-23.5M, with capital expenditures of $214.0K. FCF margin is -53.8%.
How does SONM compare to other Telecom stocks?
Vs Telecom sector averages: Net margin -46.8% (avg: 14%), ROE N/A (avg: 15%), current ratio 0.60 (avg: 1).